Characterization at Novo Nordisk (1998) Ipamorelin emerged from a GHS research program at Novo Nordisk A/S in Mlv, Denmark, in the late 1990s
,
JAMA Netw Open 3(10):e2020836 Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O et al (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: A phase 2 randomized clinical trial
Ong et al., Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021, The Lancet, vol
This is why refrigeration (28C) is specified instead of freezing (20C) for reconstituted peptides